Thryv Therapeutics to Participate in UBS, RBC Capital Markets, and Jefferies Healthcare Conferences

B Sharing Progress on a Pipeline of First-in-Class SGK1 Inhibitors Targeting High-Risk Cardiovascular Populations MONTREAL, May 12, 2026 /PRNewswire/ – Thryv Therapeutics Inc., a clinical-stage biotechnology…
posteditor
posteditor
Articles: 17424

Other News